Additionally, MCL has been demonstrated to counteract tamoxifen resistance in breast cancer (BC) by downregulating the expression of Amidohydrolase 1 (ASAH1), adjusting the ROS/AKT signaling pathway, and activating the NRF2/KEAP1 antioxidant mechanism. Here, AKT1 is linked to breast cancer.